Literature DB >> 2403979

Metabolism and production of angiotensin I in different vascular beds in subjects with hypertension.

P J Admiraal1, F H Derkx, A H Danser, H Pieterman, M A Schalekamp.   

Abstract

To study the metabolism and production of angiotensin I, highly purified monoiodinated [125I] angiotensin I was given by constant systemic intravenous infusion, either alone (n = 7) or combined with unlabeled angiotensin I (n = 5), to subjects with essential hypertension who were treated with the angiotensin converting enzyme inhibitor captopril (50 mg b.i.d.). Blood samples were taken from the aorta and the renal, antecubital, femoral, and hepatic veins. [125I]Angiotensin I and angiotensin I were extracted from plasma, separated by high-performance liquid chromatography, and quantitated by gamma counting and radioimmunoassay. Plasma renin activity was measured at pH 7.4. The plasma decay curves after discontinuation of the infusions of [125I]angiotensin I and unlabeled angiotensin I were similar for the two peptides. The regional extraction ratio of [125I]angiotensin I was 47 +/- 4% (mean +/- SEM) across the forearm, 59 +/- 3% across the leg, 81 +/- 1% across the kidneys, and 96 +/- 1% across the hepatomesenteric vascular bed. These results were not different from those obtained for infused unlabeled angiotensin I. Despite the rapid removal of arterially delivered angiotensin I, no difference was found between the venous and arterial levels of endogenous angiotensin I across the various vascular beds, with the exception of the liver where angiotensin I in the vein was 50% lower than in the aorta. Thus, 50-90% of endogenous angiotensin I in the veins appeared to be derived from regional de novo production. The blood transit time is 0.1-0.2 minute in the limbs and in the kidneys and 0.3-0.5 minute in the hepatomesenteric vascular bed. This is too short for plasma renin activity to account for the measured de novo angiotensin I production. It was calculated that less than 20-30% in the limbs and in the kidneys and approximately 60% in the hepatomesenteric region of de novo-produced angiotensin I could be accounted for by circulating renin. These results indicate that a high percentage of plasma angiotensin I may be produced locally (i.e., not in circulating plasma).

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2403979     DOI: 10.1161/01.hyp.15.1.44

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  22 in total

1.  New developments in renin and hypertension.

Authors:  N J Samani
Journal:  BMJ       Date:  1991-04-27

Review 2.  Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs.

Authors:  R J MacFadyen; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

Review 3.  Local renin-angiotensin systems.

Authors:  A H Danser
Journal:  Mol Cell Biochem       Date:  1996 Apr 12-26       Impact factor: 3.396

4.  Prolonged blood pressure reduction by orally active renin inhibitor RO 42-5892 in essential hypertension.

Authors:  A H van den Meiracker; P J Admiraal; A J Man in 't Veld; F H Derkx; H J Ritsema van Eck; P Mulder; P van Brummelen; M A Schalekamp
Journal:  BMJ       Date:  1990-07-28

5.  The serum angiotensin-converting enzyme and angiotensin II response to altered posture and acute exercise, and the influence of ACE genotype.

Authors:  David Woods; Julie Sanders; Alun Jones; Emma Hawe; Peter Gohlke; Steve E Humphries; John Payne; Hugh Montgomery
Journal:  Eur J Appl Physiol       Date:  2003-11-01       Impact factor: 3.078

6.  Angiotensin vaccination: what is the prospect of success?

Authors:  Duncan J Campbell
Journal:  Curr Hypertens Rep       Date:  2009-02       Impact factor: 5.369

7.  Assessment of the role of the renin-angiotensin system in cardiac contractility utilizing the renin inhibitor remikiren.

Authors:  J P van Kats; L M Sassen; A H Danser; M P Polak; L K Soei; F H Derkx; M A Schalekamp; P D Verdouw
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

8.  A neonate with idiopathic hyperaldosteronism.

Authors:  R H Veenhoven; J G Vande Walle; R A Donckerwolcke; J M Wit; A W Griffiven; F H Derkx; M A Schalekamp
Journal:  Pediatr Nephrol       Date:  1991-11       Impact factor: 3.714

9.  Enhanced cardiac angiotensinogen gene expression and angiotensin converting enzyme activity in tachypacing-induced heart failure in rats.

Authors:  M Finckh; W Hellmann; D Ganten; A Furtwängler; J Allgeier; M Boltz; J Holtz
Journal:  Basic Res Cardiol       Date:  1991 Jul-Aug       Impact factor: 17.165

10.  Evidence for tissue-specific activation of renal angiotensinogen mRNA expression in chronic stable experimental heart failure.

Authors:  H Schunkert; J R Ingelfinger; A T Hirsch; S S Tang; S E Litwin; C E Talsness; V J Dzau
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.